Medison Pharma, a global pharmaceutical company specializing in providing access to innovative therapies for patients worldwide, and Alnylam Pharmaceuticals, Inc., a prominent RNAi therapeutics company, have announced a significant expansion of their existing partnership.

The expansion will now encompass selected markets in Latin America (LATAM) and the Asia-Pacific (APAC) region, along with additional international markets, building upon their collaboration in Central and Eastern Europe and Israel.

Medison has developed a unique commercialization platform focused on delivering cutting-edge treatments for rare and severe diseases. With a steadfast dedication to the most innovative therapies, Medison stands as the sole partner specializing in this field.

The partnership between Alnylam and Medison was first established in 2018 and has since evolved to include various regions and markets. This expansion aims to ensure the availability of Alnylam's commercial therapies, including ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), across multiple international markets.

Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam, expressed enthusiasm about the extended partnership, stating, "We are delighted to extend yet again our existing partnership with Medison, which will enable us to enhance our presence and bring the benefits of Alnylam's innovative RNAi therapeutics to patients in additional APAC and LATAM markets."

Meir Jakobsohn, Founder and Executive Chairman of Medison, emphasized the significance of the evolving partnership, stating, "The new category of multi-regional partnerships that we have been creating in the past few years continues to gain traction with the most innovative biotech companies. We are proud of our longstanding partnership with Alnylam and will continue to work together to bridge geographical gaps, ensuring that Alnylam's life-saving therapies reach patients in need."

Gil Gurfinkel, CEO of Medison, highlighted the transformative impact of their unified commercial platform, stating, "Our unified commercial platform enables biotech companies to transform numerous complex and fragmented markets and regions into a unified territory, and we are proudly leading the trend and the category. Our expanding partnership with Alnylam shows just how our one-of-a-kind unified commercial platform, with single alliance management across multiple markets and regions, is of great value to leading biotech companies. This partnership will make Alnylam's therapies available in additional international markets, offering newfound hope for patients suffering from rare diseases."